Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0150
-0.0040 (-21.05%)
May 20, 2026, 9:30 AM EST
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 506 employees as of December 31, 2024. The number of employees increased by 57 or 12.69% compared to the previous year.
Employees
506
Change (1Y)
57
Growth (1Y)
12.69%
Revenue / Employee
$128,626
Profits / Employee
-$335,486
Market Cap
3.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 506 | 57 | 12.69% |
| Dec 31, 2023 | 449 | -85 | -15.92% |
| Dec 31, 2022 | 534 | 40 | 8.10% |
| Dec 31, 2021 | 494 | 32 | 6.93% |
| Dec 31, 2020 | 462 | 62 | 15.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Orgenesis | 77 |
| Reviva Pharmaceuticals Holdings | 14 |
| Mosaic ImmunoEngineering | 7 |
| AccuStem Sciences | 4 |
| Bioxytran | 2 |
| Synlogic | 1 |
Adaptimmune Therapeutics News
- 6 months ago - Adaptimmune Announces Changes to Board and Executive Leadership Team - Newsfile Corp
- 7 months ago - Adaptimmune Announces Delisting from Nasdaq - Newsfile Corp
- 10 months ago - Adaptimmune Reports Q2 Financial Results and Provides Business Update - Newsfile Corp
- 10 months ago - Adaptimmune Therapeutics Quarterly report: Q2 2025 - Filings
- 10 months ago - Adaptimmune Therapeutics Earnings release: Q2 2025 - Filings
- 10 months ago - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - Newsfile Corp
- 1 year ago - Adaptimmune Therapeutics Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - Adaptimmune Therapeutics Quarterly report: Q1 2025 - Filings